Patients with visceral leishmaniasis and any form of immunodeficiency, such as idiopathic CD4+ T cell lymphocytopenia or immunosuppressive therapy, must be monitored closely for signs of relapse and may benefit from secondary prophylaxis. The gene discussed is CD4; the disease is lymphopenia.